Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam

Xenobiotica

Volumn 27, Issue 9, 1997, Pages 913-922

  Senda, C ^a   Kishimoto, W ^a   Sakai, K ^a   Nagakura, A ^a   Igarashi, T ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROTIZOLAM; CIMETIDINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; LIVER MICROSOME;

AZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; HYPNOTICS AND SEDATIVES; ISOENZYMES; KINETICS; MICROSOMES, LIVER; SENSITIVITY AND SPECIFICITY;

EID: 0030762312     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240082     Document Type: Article

References (18)

1. BADCOCK, N. R., BARTHOLOMEUSZ, F. D., FREWIN, D. B., SANSOM, L. N. and REID, J. G., 1987, The pharmacokinetics of ketoconazole after chronic administration in adults. European Journal of Clinical Pharmacology, 33, 531-534.
2. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYLTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
3. 14C]-brotizolam in the rat, dog, monkey and man. Arzneimittelforschng, 36, 578-586.
4. 14C]-brotizolam in humans. Arzneimittelforschng, 36, 575-578.
5. GONZALEZ, F. J., 1992, Human cytochromes P450: problems and prospects. Trends in Pharmacological Science, 13, 346-352.
6. GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133-138.
7. GUENGERICH, F. P., MULLER-ENOCH, D. and BLAIR, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 287-295.
8. HORAI, Y. and ISHIZAKI, T., 1988, Pharmacogenetics and its clinical implications part II. Oxidation polymorphism. Rational Drug Therapy, 22, 1-8.
9. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
10. MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
11. NEWTON, D. J., WANG, R. W. and LU, Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
12. SANOHEZ-MARTINEZ, J. and LANDA-PALOS, D. M. J., 1982, A new thienodiazepine, brotizolam, for the treatment of insomnia. Journal of International Medical Research, 10, 118-121.
13. TALLARIDA, R. J. and MURRAY, R. B., 1986, Manual of Pharmacologic Calculations with Computer Programs (New York: Springer).
14. VARHE, A., OLKKOLA, K. T. and NEUVONEN, P. J., 1994, Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 56, 601-607.
15. VON MOUTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
16. VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., CONTREAU-BIBBO, M. M., PRICHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam bio-transformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370-379.
17. WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1′-hydroxy-midazolam formation by ketoconazole, nifedipine, erythromycin, cimitidine, and nizatidine. Pharmaceutical Research, 11, 921-924.
18. YASUI, N., OTANI, K., KANEKO, S., OHKUBO, T., OSANAI, T., SUGAWARA, K., CHIBA, K. and ISHIZAKI, T., 1996, A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapeutics, 59, 514-519.